M. Johnson

发表

LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study

A. Dingemans, J. Mazières, M. Schuler, 2022, Annals of Oncology.

LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation

J. Christensen, S. Ou, R. Yaeger, 2021, Annals of Oncology.

728O Results from phase I dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors

D. Davar, M. Callahan, F. Thistlethwaite, 2022, Annals of Oncology.

Successful control of lymphangioma circumscriptum by superficial X‐rays

A. Rostom, M. Johnson, S. O’Cathail, 1985, The British journal of dermatology.

EP02.04-005 Phase II NAUTIKA1 Study of Targeted Therapies in Stage II-III NSCLC: Preliminary Data of Neoadjuvant Alectinib for ALK+ NSCLC

J. Chaft, B. Sepesi, E. Toloza, 2022, Journal of Thoracic Oncology.

453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study

S. Piha-Paul, Shin-ichiro Takahashi, M. Awad, 2022, Annals of Oncology.

1550TiP Phase II, multicenter, randomized, open-label study of DS-7300 in patients (pts) with pre-treated extensive-stage small cell lung cancer (ES-SCLC)

C. Rudin, C. Hann, L. Paz-Ares, 2022, Annals of Oncology.

488P Phase I trial of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in follicular lymphoma (FL), small cell lung cancer (SCLC) and castration-resistant prostate cancer (CRPC)

A. Tolcher, V. Vorobyev, A. Choudhury, 2022, Annals of Oncology.

LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC

T. Hoang, M. Huang, D. Rodríguez-Abreu, 2021, Annals of Oncology.

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small cell lung cancer.

F. Hodi, S. Gettinger, T. Mok, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

OA15.04 Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC

E. Garon, S. Kim, M. Hussein, 2022, Journal of Thoracic Oncology.